O	O	O	0	11	Concomitant	Concomitant	B-NP	JJ	O	2	NMOD	O
O	O	O	12	26	downregulation	downregulation	I-NP	NN	O	21	NMOD	O
O	O	O	27	29	of	of	B-PP	IN	O	2	NMOD	O
T5	B-Entity	B-Entity	30	33	IgH	IgH	B-NP	NN	B-DNA	7	NMOD	B-DNA
T5	I-Entity	I-Entity	34	35	3	3	I-NP	CD	I-DNA	7	NMOD	I-DNA
T5	I-Entity	I-Entity	35	36	'	'	I-NP	SYM	I-DNA	7	NMOD	I-DNA
T5	I-Entity	I-Entity	37	45	enhancer	enhancer	I-NP	NN	I-DNA	8	NMOD	I-DNA
O	O	O	46	54	activity	activity	I-NP	NN	O	13	NMOD	O
O	O	O	55	58	and	and	I-NP	CC	O	13	NMOD	O
T1	B-Protein	B-Protein	59	60	c	c	I-NP	NN	O	13	NMOD	O
T1	I-Protein	I-Protein	60	61	-	-	B-NP	HYPH	O	13	NMOD	O
T1	I-Protein	I-Protein	61	64	myc	myc	I-NP	NN	B-protein	13	NMOD	B-protein
O	O	O	65	75	expression	expression	I-NP	NN	O	3	PMOD	O
O	O	O	76	78	in	in	B-PP	IN	O	2	NMOD	O
O	O	O	79	80	a	a	B-NP	DT	O	19	NMOD	O
O	O	O	81	93	plasmacytoma	plasmacytoma	I-NP	NN	O	19	NMOD	O
O	O	O	94	95	x	x	I-NP	NN	O	19	NMOD	O
O	O	O	96	106	fibroblast	fibroblast	I-NP	NN	O	19	NMOD	O
O	O	O	107	118	environment	environment	I-NP	NN	O	14	PMOD	O
O	O	O	118	119	:	:	O	:	O	2	P	O
O	O	O	120	132	implications	implication	B-NP	NNS	O	0	ROOT	O
O	O	O	133	136	for	for	B-PP	IN	O	21	NMOD	O
O	O	O	137	150	dysregulation	dysregulation	B-NP	NN	O	22	PMOD	O
O	O	O	151	153	of	of	B-PP	IN	O	23	NMOD	O
O	O	O	154	166	translocated	translocate	B-NP	VBN	O	28	NMOD	O
T2	B-Protein	B-Protein	167	168	c	c	I-NP	NN	B-DNA	28	NMOD	B-DNA
T2	I-Protein	I-Protein	168	169	-	-	I-NP	HYPH	I-DNA	28	NMOD	I-DNA
T2	I-Protein	I-Protein	169	172	myc	myc	I-NP	NN	I-DNA	24	PMOD	I-DNA
O	O	O	172	173	.	.	O	.	O	21	P	O

O	O	O	175	185	Regulation	Regulation	B-NP	NN	O	11	SUB	O
O	O	O	186	188	of	of	B-PP	IN	O	1	NMOD	O
T6	B-Entity	B-Entity	189	203	immunoglobulin	immunoglobulin	B-NP	NN	B-DNA	5	NMOD	B-DNA
T6	I-Entity	I-Entity	204	209	heavy	heavy	I-NP	JJ	I-DNA	5	NMOD	I-DNA
T6	I-Entity	I-Entity	210	215	chain	chain	I-NP	NN	I-DNA	9	NMOD	I-DNA
T6	I-Entity	I-Entity	216	217	(	(	O	(	I-DNA	9	NMOD	I-DNA
T6	I-Entity	I-Entity	217	220	IgH	IgH	B-NP	NN	I-DNA	9	NMOD	I-DNA
T6	I-Entity	I-Entity	220	221	)	)	O	)	I-DNA	9	NMOD	I-DNA
T6	I-Entity	I-Entity	222	226	gene	gene	B-NP	NN	I-DNA	10	NMOD	I-DNA
O	O	O	227	237	expression	expression	I-NP	NN	O	2	PMOD	O
O	O	O	238	240	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	241	251	controlled	control	I-VP	VBN	O	11	VC	O
O	O	O	252	254	by	by	B-PP	IN	O	12	VMOD	O
O	O	O	255	256	a	a	B-NP	DT	O	19	NMOD	O
T7	B-Entity	B-Entity	257	258	B	B	I-NP	NN	B-DNA	16	NMOD	B-DNA
T7	I-Entity	I-Entity	259	263	cell	cell	I-NP	NN	I-DNA	19	NMOD	I-DNA
T7	I-Entity	I-Entity	263	264	-	-	B-NP	HYPH	I-DNA	19	NMOD	I-DNA
T7	I-Entity	I-Entity	264	272	specific	specific	I-NP	JJ	I-DNA	19	NMOD	I-DNA
T7,T8	I-Entity,B-Entity	I-Entity,B-Entity	273	281	promoter	promoter	I-NP	NN	I-DNA	26	NMOD	I-DNA
O	O	O	281	282	,	,	O	,	O	26	P	O
T9	B-Entity	B-Entity	283	291	intronic	intronic	B-NP	JJ	B-DNA	22	NMOD	B-DNA
T9	I-Entity	I-Entity	292	300	enhancer	enhancer	I-NP	NN	I-DNA	26	NMOD	I-DNA
O	O	O	301	304	and	and	O	CC	O	26	NMOD	O
O	O	O	305	315	additional	additional	B-NP	JJ	O	26	NMOD	O
T10	B-Entity	B-Entity	316	317	B	B	I-NP	NN	O	26	NMOD	O
T10	I-Entity	I-Entity	318	322	cell	cell	I-NP	NN	O	30	NMOD	O
T10	I-Entity	I-Entity	322	323	-	-	B-NP	HYPH	O	30	P	O
T10	I-Entity	I-Entity	323	331	specific	specific	I-NP	JJ	O	30	NMOD	O
T10,T11	I-Entity,B-Entity	I-Entity,B-Entity	332	340	enhancer	enhancer	I-NP	NN	B-DNA	30	NMOD	B-DNA
T10,T11	I-Entity,I-Entity	I-Entity,I-Entity	341	349	elements	element	I-NP	NNS	I-DNA	13	PMOD	I-DNA
O	O	O	350	360	identified	identify	B-VP	VBN	O	30	NMOD	O
O	O	O	361	369	recently	recently	B-ADVP	RB	O	31	VMOD	O
O	O	O	370	372	in	in	B-PP	IN	O	31	VMOD	O
O	O	O	373	376	the	the	B-NP	DT	O	37	NMOD	O
O	O	O	377	378	3	3	I-NP	CD	B-DNA	37	NMOD	B-DNA
O	O	O	378	379	'	'	I-NP	SYM	I-DNA	37	NMOD	I-DNA
O	O	O	380	383	end	end	I-NP	NN	I-DNA	33	PMOD	I-DNA
O	O	O	384	386	of	of	B-PP	IN	O	37	NMOD	O
O	O	O	387	390	the	the	B-NP	DT	O	41	NMOD	O
T12	B-Entity	B-Entity	391	394	IgH	IgH	I-NP	NN	B-DNA	41	NMOD	B-DNA
T12	I-Entity	I-Entity	395	400	locus	locus	I-NP	NN	I-DNA	38	PMOD	I-DNA
O	O	O	400	401	.	.	O	.	O	11	P	O

O	O	O	402	405	One	One	B-NP	CD	O	11	NMOD	O
O	O	O	406	408	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	409	412	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	413	419	latter	latter	I-NP	JJ	B-DNA	5	NMOD	B-DNA
O	O	O	420	428	elements	element	I-NP	NNS	I-DNA	2	PMOD	I-DNA
O	O	O	428	429	,	,	O	,	O	11	P	O
O	O	O	430	433	the	the	B-NP	DT	O	11	NMOD	O
T13	B-Entity	B-Entity	434	437	IgH	IgH	I-NP	NN	B-DNA	11	NMOD	B-DNA
T13	I-Entity	I-Entity	438	439	3	3	I-NP	CD	I-DNA	11	NMOD	I-DNA
T13	I-Entity	I-Entity	439	440	'	'	I-NP	SYM	I-DNA	11	NMOD	I-DNA
T13	I-Entity	I-Entity	441	449	enhancer	enhancer	I-NP	NN	I-DNA	13	SUB	I-DNA
O	O	O	449	450	,	,	O	,	O	11	P	O
O	O	O	451	453	is	be	B-VP	VBZ	O	87	VMOD	O
O	O	O	454	456	of	of	B-PP	IN	O	13	PRD	O
O	O	O	457	467	particular	particular	B-NP	JJ	O	16	NMOD	O
O	O	O	468	476	interest	interest	I-NP	NN	O	14	PMOD	O
O	O	O	476	477	:	:	O	:	O	87	P	O
O	O	O	478	479	(	(	B-LST	(	O	19	DEP	O
O	O	O	479	480	1	1	I-LST	LS	O	22	VMOD	O
O	O	O	480	481	)	)	O	)	O	19	DEP	O
O	O	O	482	484	it	it	B-NP	PRP	O	22	SUB	O
O	O	O	485	487	is	be	B-VP	VBZ	O	87	VMOD	O
O	O	O	488	489	B	B	B-NP	NN	O	24	NMOD	O
O	O	O	490	494	cell	cell	I-NP	NN	O	28	AMOD	O
O	O	O	494	495	-	-	O	HYPH	O	24	P	O
O	O	O	495	503	specific	specific	B-ADJP	JJ	O	24	AMOD	O
O	O	O	504	507	and	and	I-ADJP	CC	O	28	AMOD	O
O	O	O	508	514	active	active	I-ADJP	JJ	O	22	PRD	O
O	O	O	515	519	only	only	B-PP	RB	O	30	PMOD	O
O	O	O	520	522	in	in	I-PP	IN	O	28	AMOD	O
O	O	O	523	527	late	late	B-NP	JJ	O	34	NMOD	O
O	O	O	528	529	B	B	I-NP	NN	O	34	NMOD	O
O	O	O	530	534	cell	cell	I-NP	NN	O	34	NMOD	O
O	O	O	535	546	development	development	I-NP	NN	O	30	PMOD	O
O	O	O	546	547	;	;	O	:	O	87	P	O
O	O	O	548	549	(	(	B-LST	(	O	37	DEP	O
O	O	O	549	550	2	2	I-LST	LS	O	48	VMOD	O
O	O	O	550	551	)	)	O	)	O	37	DEP	O
O	O	O	552	554	in	in	B-PP	IN	O	48	VMOD	O
O	O	O	555	561	rodent	rodent	B-NP	JJ	O	41	NMOD	O
O	O	O	562	575	plasmacytomas	plasmacytoma	I-NP	NNS	O	39	PMOD	O
O	O	O	576	579	and	and	B-PP	CC	O	39	PMOD	O
O	O	O	580	582	in	in	B-PP	IN	O	39	PMOD	O
O	O	O	583	587	some	some	B-NP	DT	O	46	NMOD	O
O	O	O	588	593	human	human	I-NP	JJ	O	46	NMOD	O
O	O	O	594	601	Burkitt	Burkitt	I-NP	NN	O	43	PMOD	O
O	O	O	601	602	'	'	O	''	O	46	NMOD	O
O	O	O	602	603	s	s	B-VP	VBZ	O	87	VMOD	O
O	O	O	604	613	lymphomas	lymphoma	B-NP	NNS	O	48	OBJ	O
O	O	O	614	616	it	it	B-NP	PRP	O	48	OBJ	O
O	O	O	617	619	is	be	B-VP	VBZ	O	48	VMOD	O
O	O	O	620	624	part	part	B-NP	NN	O	51	PRD	O
O	O	O	625	627	of	of	B-PP	IN	O	52	NMOD	O
O	O	O	628	629	a	a	B-NP	DT	O	57	NMOD	O
T14	B-Entity	B-Entity	630	635	locus	locus	I-NP	NN	B-DNA	57	NMOD	B-DNA
T14	I-Entity	I-Entity	636	643	control	control	I-NP	NN	I-DNA	57	NMOD	I-DNA
T14	I-Entity	I-Entity	644	650	region	region	I-NP	NN	I-DNA	53	PMOD	I-DNA
O	O	O	651	652	(	(	O	(	O	60	DEP	O
T15	B-Entity	B-Entity	652	655	LCR	LCR	B-NP	NN	B-DNA	60	DEP	B-DNA
O	O	O	655	656	)	)	O	)	O	57	NMOD	O
O	O	O	657	661	that	that	B-NP	WDT	O	57	NMOD	O
O	O	O	662	664	is	be	B-VP	VBZ	O	61	SBAR	O
O	O	O	665	673	involved	involve	I-VP	VBN	O	62	VC	O
O	O	O	674	676	in	in	B-PP	IN	O	63	VMOD	O
O	O	O	677	689	deregulation	deregulation	B-NP	NN	O	64	PMOD	O
O	O	O	690	692	of	of	B-PP	IN	O	65	NMOD	O
O	O	O	693	696	the	the	B-NP	DT	O	71	NMOD	O
T3	B-Protein	B-Protein	697	698	c	c	I-NP	NN	B-DNA	71	NMOD	B-DNA
T3	I-Protein	I-Protein	698	699	-	-	B-NP	HYPH	I-DNA	71	NMOD	I-DNA
T3	I-Protein	I-Protein	699	702	myc	myc	I-NP	NN	I-DNA	71	NMOD	I-DNA
O	O	O	703	711	oncogene	oncogene	I-NP	NN	I-DNA	66	PMOD	I-DNA
O	O	O	712	714	as	as	B-PP	IN	O	63	VMOD	O
O	O	O	715	716	a	a	B-NP	DT	O	74	NMOD	O
O	O	O	717	723	result	result	I-NP	NN	O	72	PMOD	O
O	O	O	724	726	of	of	B-PP	IN	O	74	NMOD	O
O	O	O	727	740	translocation	translocation	B-NP	NN	O	75	PMOD	O
O	O	O	741	745	into	into	B-PP	IN	O	76	NMOD	O
O	O	O	746	749	the	the	B-NP	DT	O	80	NMOD	O
T16	B-Entity	B-Entity	750	753	IgH	IgH	I-NP	NN	B-DNA	80	NMOD	B-DNA
T16	I-Entity	I-Entity	754	759	locus	locus	I-NP	NN	I-DNA	77	PMOD	I-DNA
O	O	O	759	760	;	;	O	:	O	87	P	O
O	O	O	761	764	and	and	O	CC	O	87	VMOD	O
O	O	O	765	766	(	(	B-LST	(	O	84	DEP	O
O	O	O	766	767	3	3	I-LST	LS	O	87	VMOD	O
O	O	O	767	768	)	)	O	)	O	84	DEP	O
O	O	O	769	771	it	it	B-NP	PRP	O	87	SUB	O
O	O	O	772	775	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	776	780	been	be	I-VP	VBN	O	87	VC	O
O	O	O	781	791	implicated	implicate	I-VP	VBN	O	88	VC	O
O	O	O	792	794	in	in	B-PP	IN	O	89	VMOD	O
O	O	O	795	798	the	the	B-NP	DT	O	92	NMOD	O
O	O	O	799	809	mechanisms	mechanism	I-NP	NNS	O	90	PMOD	O
O	O	O	810	814	that	that	B-NP	WDT	O	92	NMOD	O
O	O	O	815	822	control	control	B-VP	VBP	O	93	SBAR	O
T17	B-Entity	B-Entity	823	825	Ig	Ig	B-NP	NN	B-DNA	97	NMOD	B-DNA
T17	I-Entity	I-Entity	826	830	gene	gene	I-NP	NN	I-DNA	97	NMOD	I-DNA
T17	I-Entity	I-Entity	831	836	class	class	I-NP	NN	O	99	NMOD	O
O	O	O	837	843	switch	switch	I-NP	NN	O	99	NMOD	O
O	O	O	844	857	recombination	recombination	I-NP	NN	O	94	OBJ	O
O	O	O	857	858	.	.	O	.	O	87	P	O

O	O	O	859	861	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	862	866	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	867	871	used	use	I-VP	VBN	O	2	VC	O
O	O	O	872	873	a	a	B-NP	DT	O	8	NMOD	O
O	O	O	874	881	somatic	somatic	I-NP	JJ	O	8	NMOD	O
O	O	O	882	886	cell	cell	I-NP	NN	O	8	NMOD	O
O	O	O	887	900	hybridization	hybridization	I-NP	NN	O	8	NMOD	O
O	O	O	901	909	approach	approach	I-NP	NN	O	3	OBJ	O
O	O	O	910	912	to	to	B-VP	TO	O	11	VMOD	O
O	O	O	913	924	genetically	genetically	I-VP	RB	O	11	VMOD	O
O	O	O	925	932	analyse	analyse	I-VP	VB	O	2	VMOD	O
O	O	O	933	943	regulation	regulation	B-NP	NN	O	11	OBJ	O
O	O	O	944	946	of	of	B-PP	IN	O	12	NMOD	O
O	O	O	947	950	the	the	B-NP	DT	O	15	NMOD	O
O	O	O	951	959	activity	activity	I-NP	NN	O	13	PMOD	O
O	O	O	960	962	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	963	966	the	the	B-NP	DT	O	21	NMOD	O
T18	B-Entity	B-Entity	967	970	IgH	IgH	I-NP	NN	B-DNA	21	NMOD	B-DNA
T18	I-Entity	I-Entity	971	972	3	3	I-NP	CD	I-DNA	21	NMOD	I-DNA
T18	I-Entity	I-Entity	972	973	'	'	I-NP	SYM	I-DNA	21	NMOD	I-DNA
T18	I-Entity	I-Entity	974	982	enhancer	enhancer	I-NP	NN	I-DNA	16	PMOD	I-DNA
O	O	O	982	983	.	.	O	.	O	2	P	O

O	O	O	984	988	When	When	B-ADVP	WRB	O	24	VMOD	O
O	O	O	989	994	mouse	mouse	B-NP	NN	B-cell_line	5	NMOD	B-cell_line
O	O	O	995	1000	MPC11	MPC11	I-NP	NN	I-cell_line	5	NMOD	I-cell_line
O	O	O	1001	1013	plasmacytoma	plasmacytoma	I-NP	NN	I-cell_line	5	NMOD	I-cell_line
O	O	O	1014	1019	cells	cell	I-NP	NNS	I-cell_line	17	SUB	I-cell_line
O	O	O	1019	1020	,	,	O	,	O	5	P	O
O	O	O	1021	1023	in	in	B-PP	IN	O	5	NMOD	O
O	O	O	1024	1029	which	which	B-NP	WDT	O	7	PMOD	O
O	O	O	1030	1033	the	the	B-NP	DT	O	13	NMOD	O
T19	B-Entity	B-Entity	1034	1037	IgH	IgH	I-NP	NN	B-DNA	13	NMOD	B-DNA
T19	I-Entity	I-Entity	1038	1039	3	3	I-NP	CD	I-DNA	13	NMOD	I-DNA
T19	I-Entity	I-Entity	1039	1040	'	'	I-NP	SYM	I-DNA	13	NMOD	I-DNA
T19	I-Entity	I-Entity	1041	1049	enhancer	enhancer	I-NP	NN	I-DNA	14	SUB	I-DNA
O	O	O	1050	1052	is	be	B-VP	VBZ	O	7	SBAR	O
O	O	O	1053	1059	active	active	B-ADJP	JJ	O	14	PRD	O
O	O	O	1059	1060	,	,	O	,	O	5	P	O
O	O	O	1061	1064	are	be	B-VP	VBP	O	1	SBAR	O
O	O	O	1065	1070	fused	fuse	I-VP	VBN	O	17	VC	O
O	O	O	1071	1075	with	with	B-PP	IN	O	18	VMOD	O
O	O	O	1076	1087	fibroblasts	fibroblast	B-NP	NNS	B-cell_type	19	PMOD	B-cell_type
O	O	O	1087	1088	,	,	O	,	O	24	P	O
O	O	O	1089	1091	Ig	Ig	B-NP	NN	B-protein	23	NMOD	B-protein
O	O	O	1092	1102	expression	expression	I-NP	NN	O	24	SUB	O
O	O	O	1103	1105	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1106	1118	extinguished	extinguish	I-VP	VBN	O	24	VC	O
O	O	O	1119	1121	at	at	B-PP	IN	O	25	VMOD	O
O	O	O	1122	1125	the	the	B-NP	DT	O	28	NMOD	O
O	O	O	1126	1131	level	level	I-NP	NN	O	26	PMOD	O
O	O	O	1132	1134	of	of	B-PP	IN	O	28	NMOD	O
O	O	O	1135	1148	transcription	transcription	B-NP	NN	O	29	PMOD	O
O	O	O	1148	1149	.	.	O	.	O	24	P	O

O	O	O	1150	1154	Here	Here	B-ADVP	RB	O	3	VMOD	O
O	O	O	1155	1157	we	we	B-NP	PRP	O	3	SUB	O
O	O	O	1158	1162	show	show	B-VP	VBP	O	0	ROOT	O
O	O	O	1163	1167	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	O	1168	1170	in	in	B-PP	IN	O	18	VMOD	O
O	O	O	1171	1172	a	a	B-NP	DT	O	11	NMOD	O
O	O	O	1173	1178	MPC11	MPC11	I-NP	NN	B-cell_line	11	NMOD	B-cell_line
O	O	O	1179	1191	plasmacytoma	plasmacytoma	I-NP	NN	I-cell_line	11	NMOD	I-cell_line
O	O	O	1192	1193	x	x	I-NP	NN	I-cell_line	11	NMOD	I-cell_line
O	O	O	1194	1204	fibroblast	fibroblast	I-NP	NN	I-cell_line	11	NMOD	I-cell_line
O	O	O	1205	1216	environment	environment	I-NP	NN	I-cell_line	5	PMOD	I-cell_line
O	O	O	1216	1217	,	,	O	,	O	18	P	O
O	O	O	1218	1221	the	the	B-NP	DT	O	17	NMOD	O
T20	B-Entity	B-Entity	1222	1225	IgH	IgH	I-NP	NN	B-DNA	17	NMOD	B-DNA
T20	I-Entity	I-Entity	1226	1227	3	3	I-NP	CD	I-DNA	17	NMOD	I-DNA
T20	I-Entity	I-Entity	1227	1228	'	'	I-NP	SYM	I-DNA	17	NMOD	I-DNA
T20	I-Entity	I-Entity	1229	1237	enhancer	enhancer	I-NP	NN	I-DNA	18	SUB	I-DNA
O	O	O	1238	1240	is	be	B-VP	VBZ	O	4	SBAR	O
O	O	O	1241	1258	transcriptionally	transcriptionally	B-ADJP	RB	O	20	AMOD	O
O	O	O	1259	1267	inactive	inactive	I-ADJP	JJ	O	18	PRD	O
O	O	O	1267	1268	.	.	O	.	O	3	P	O

O	O	O	1269	1280	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD	O
O	O	O	1280	1281	,	,	O	,	O	4	P	O
O	O	O	1282	1284	we	we	B-NP	PRP	O	4	SUB	O
O	O	O	1285	1296	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	O	1297	1301	that	that	B-SBAR	IN	O	4	VMOD	O
O	O	O	1302	1309	binding	binding	B-NP	NN	O	24	SUB	O
O	O	O	1310	1312	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	1313	1320	several	several	B-NP	JJ	O	10	NMOD	O
O	O	O	1321	1322	B	B	I-NP	NN	O	10	NMOD	O
O	O	O	1323	1327	cell	cell	I-NP	NN	O	14	NMOD	O
O	O	O	1327	1328	-	-	B-NP	HYPH	O	14	P	O
O	O	O	1328	1336	specific	specific	I-NP	JJ	O	14	NMOD	O
O	O	O	1337	1350	transcription	transcription	I-NP	NN	B-protein	14	NMOD	B-protein
O	O	O	1351	1358	factors	factor	I-NP	NNS	I-protein	7	PMOD	I-protein
O	O	O	1358	1359	,	,	O	,	O	14	P	O
O	O	O	1360	1369	essential	essential	B-ADJP	JJ	O	14	NMOD	O
O	O	O	1370	1373	for	for	B-PP	IN	O	16	AMOD	O
T21	B-Entity	B-Entity	1374	1377	IgH	IgH	B-NP	NN	B-DNA	22	NMOD	B-DNA
T21	I-Entity	I-Entity	1378	1379	3	3	I-NP	CD	I-DNA	18	NMOD	I-DNA
T21	I-Entity	I-Entity	1379	1380	'	'	I-NP	SYM	I-DNA	22	NMOD	I-DNA
T21	I-Entity	I-Entity	1381	1389	enhancer	enhancer	I-NP	NN	I-DNA	22	NMOD	I-DNA
O	O	O	1390	1398	activity	activity	I-NP	NN	O	17	PMOD	O
O	O	O	1398	1399	,	,	O	,	O	6	P	O
O	O	O	1400	1402	is	be	B-VP	VBZ	O	5	SBAR	O
O	O	O	1403	1410	lacking	lack	I-VP	VBG	O	24	VC	O
O	O	O	1410	1411	,	,	O	,	O	24	P	O
O	O	O	1412	1417	which	which	B-NP	WDT	O	24	VMOD	O
O	O	O	1418	1421	may	may	B-VP	MD	O	27	SBAR	O
O	O	O	1422	1429	explain	explain	I-VP	VB	O	28	VC	O
O	O	O	1430	1431	3	3	B-NP	CD	O	32	AMOD	O
O	O	O	1431	1432	'	'	I-NP	SYM	O	32	AMOD	O
O	O	O	1433	1441	enhancer	enhancer	I-NP	NN	O	33	NMOD	O
O	O	O	1442	1452	inactivity	inactivity	I-NP	NN	O	29	OBJ	O
O	O	O	1452	1453	,	,	O	,	O	24	P	O
O	O	O	1454	1462	although	although	B-SBAR	IN	O	24	VMOD	O
O	O	O	1463	1466	the	the	B-NP	DT	O	37	NMOD	O
O	O	O	1467	1474	binding	binding	I-NP	NN	O	40	SUB	O
O	O	O	1475	1477	of	of	B-PP	IN	O	37	NMOD	O
O	O	O	1478	1488	repressors	repressor	B-NP	NNS	O	38	PMOD	O
O	O	O	1489	1495	cannot	cannot	B-VP	MD	O	35	SBAR	O
O	O	O	1496	1498	be	be	I-VP	VB	O	40	VC	O
O	O	O	1499	1507	excluded	exclude	I-VP	VBN	O	41	VC	O
O	O	O	1507	1508	.	.	O	.	O	4	P	O

O	O	O	1509	1517	Moreover	Moreover	B-ADVP	RB	O	28	VMOD	O
O	O	O	1517	1518	,	,	O	,	O	28	P	O
O	O	O	1519	1522	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	1523	1527	high	high	I-NP	JJ	O	6	NMOD	O
O	O	O	1528	1538	expression	expression	I-NP	NN	O	6	NMOD	O
O	O	O	1539	1544	level	level	I-NP	NN	O	28	SUB	O
O	O	O	1545	1547	of	of	B-PP	IN	O	6	NMOD	O
T4	B-Protein	B-Protein	1548	1549	c	c	B-NP	NN	O	10	NMOD	O
T4	I-Protein	I-Protein	1549	1550	-	-	I-NP	HYPH	O	10	P	O
T4	I-Protein	I-Protein	1550	1553	myc	myc	I-NP	NN	B-protein	7	PMOD	B-protein
O	O	O	1553	1554	,	,	O	,	O	6	P	O
O	O	O	1555	1569	characteristic	characteristic	B-ADJP	JJ	O	6	NMOD	O
O	O	O	1570	1572	of	of	B-PP	IN	O	12	AMOD	O
O	O	O	1573	1576	the	the	B-NP	DT	O	17	NMOD	O
O	O	O	1577	1585	parental	parental	I-NP	JJ	O	17	NMOD	O
O	O	O	1586	1591	MPC11	MPC11	I-NP	NN	B-cell_line	17	NMOD	B-cell_line
O	O	O	1592	1597	cells	cell	I-NP	NNS	I-cell_line	13	PMOD	I-cell_line
O	O	O	1598	1606	carrying	carry	B-VP	VBG	O	17	NMOD	O
O	O	O	1607	1610	the	the	B-NP	DT	O	26	NMOD	O
O	O	O	1611	1612	t	t	I-NP	NN	B-DNA	26	NMOD	B-DNA
O	O	O	1612	1613	(	(	O	(	I-DNA	25	DEP	I-DNA
O	O	O	1613	1615	12	12	B-NP	CD	I-DNA	24	NMOD	I-DNA
O	O	O	1615	1616	;	;	O	:	I-DNA	24	P	I-DNA
O	O	O	1616	1618	15	15	B-NP	CD	I-DNA	25	DEP	I-DNA
O	O	O	1618	1619	)	)	O	)	I-DNA	20	NMOD	I-DNA
O	O	O	1620	1633	translocation	translocation	B-NP	NN	I-DNA	18	OBJ	I-DNA
O	O	O	1633	1634	,	,	O	,	O	6	P	O
O	O	O	1635	1637	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1638	1642	down	down	B-ADVP	RB	O	28	VMOD	O
O	O	O	1642	1643	-	-	B-NP	HYPH	O	28	P	O
O	O	O	1643	1652	regulated	regulate	B-VP	VBN	O	28	VC	O
O	O	O	1653	1655	in	in	B-PP	IN	O	31	VMOD	O
O	O	O	1656	1659	the	the	B-NP	DT	O	34	NMOD	O
O	O	O	1660	1667	hybrids	hybrid	I-NP	NNS	B-cell_line	32	PMOD	B-cell_line
O	O	O	1668	1670	to	to	B-PP	TO	O	31	VMOD	O
O	O	O	1671	1675	that	that	B-NP	DT	O	35	PMOD	O
O	O	O	1676	1678	in	in	B-PP	IN	O	36	NMOD	O
O	O	O	1679	1686	unfused	unfused	B-NP	JJ	B-cell_type	39	NMOD	B-cell_type
O	O	O	1687	1698	fibroblasts	fibroblast	I-NP	NNS	I-cell_type	37	PMOD	I-cell_type
O	O	O	1698	1699	.	.	O	.	O	28	P	O

O	O	O	1700	1709	Therefore	Therefore	B-ADVP	RB	O	10	VMOD	O
O	O	O	1709	1710	,	,	O	,	O	10	P	O
O	O	O	1711	1723	inactivation	inactivation	B-NP	NN	O	10	SUB	O
O	O	O	1724	1726	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	1727	1730	the	the	B-NP	DT	O	9	NMOD	O
T22	B-Entity	B-Entity	1731	1734	IgH	IgH	I-NP	NN	B-DNA	9	NMOD	B-DNA
T22	I-Entity	I-Entity	1735	1736	3	3	I-NP	CD	I-DNA	9	NMOD	I-DNA
T22	I-Entity	I-Entity	1736	1737	'	'	I-NP	SYM	I-DNA	9	NMOD	I-DNA
T22	I-Entity	I-Entity	1738	1746	enhancer	enhancer	I-NP	NN	I-DNA	4	PMOD	I-DNA
O	O	O	1747	1749	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1750	1751	a	a	B-NP	DT	O	13	NMOD	O
O	O	O	1752	1766	multifactorial	multifactorial	I-NP	JJ	O	13	NMOD	O
O	O	O	1767	1774	process	process	I-NP	NN	O	10	PRD	O
O	O	O	1775	1784	affecting	affect	B-VP	VBG	O	13	NMOD	O
O	O	O	1785	1792	several	several	B-NP	JJ	O	14	OBJ	O
O	O	O	1793	1806	transcription	transcription	I-NP	NN	B-protein	17	NMOD	B-protein
O	O	O	1807	1814	factors	factor	I-NP	NNS	I-protein	15	NMOD	I-protein
O	O	O	1815	1819	that	that	B-NP	WDT	O	15	NMOD	O
O	O	O	1820	1827	control	control	B-VP	VBP	O	18	SBAR	O
O	O	O	1828	1831	the	the	B-NP	DT	O	26	NMOD	O
O	O	O	1832	1836	cell	cell	I-NP	NN	O	26	NMOD	O
O	O	O	1836	1837	-	-	B-NP	HYPH	O	26	NMOD	O
O	O	O	1837	1845	specific	specific	I-NP	JJ	O	26	NMOD	O
O	O	O	1846	1849	and	and	I-NP	CC	O	26	NMOD	O
O	O	O	1850	1863	developmental	developmental	I-NP	JJ	O	26	NMOD	O
O	O	O	1864	1872	activity	activity	I-NP	NN	O	19	OBJ	O
O	O	O	1873	1875	of	of	B-PP	IN	O	26	NMOD	O
O	O	O	1876	1879	the	the	B-NP	DT	O	29	NMOD	O
T23	B-Entity	B-Entity	1880	1888	enhancer	enhancer	I-NP	NN	B-DNA	27	PMOD	B-DNA
O	O	O	1888	1889	.	.	O	.	O	10	P	O
